Abstract
Systemic lupus erythematosus (SLE) is characterized by overactive B cells that differentiate into autoantibody-forming cells, aberrant T cell function that provides helping B cells produce autoantibodies, and overproduction of proinflammatory cytokines. However, immunodysregulation in lupus pathogenensis remains incomplete. We examined mitogen-stimulated production of proinflammatory cytokines, cell proliferation, T cell activation, and T cell apoptosisin vitro in pristane-induced lupus BALB/c mice compared to normal mice. LPS-stimulated production of IL-6 and IL-10 by splenocytes and macrophages from pristane-induced lupus mice were remarkably up-regulated compared to normal mice, whereas production of macrophage TNF-α was significantly down-regulated. Moreover,in vitro production of IL-2, IL-6, IL-10 and IFN-γ by Con A-stimulated splenocytes, cell proliferation in LPS- or Con A-stimulated- thymocytes and splenocytes, and expression of CD69+CD4+ T cells in Con A-stimulated splenocytes were greatly increased in cells derived from pristane-induced lupus mice compared to normal mice. In addition, splenic T cells and CD4+ T cells in thymocytes from pristane-induced lupus mice were more resistant than nonautoimmune normal cells to Con A-induced apoptosis. Our findings indicate that immunoregulatory abnormalities of T cells and hyperreactivity of B cells in thein vitro immune responses in pristane-induced lupus mice may explain some of lupus pathogenesis.
Similar content being viewed by others
References
Andrade, F., Casciola-Rosen, L, and Rosen, A., Apoptosis in systemic lupus erythematosus: clinical implications.Rheum. Dis. Clin. North Am., 26, 215–227 (2000).
Aringer, M. and Smolen, J. S., SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus.Arthritis Res. Ther, 5, 172–177(2003).
Crispin, J. C, Martinez, A., de Pablo, P., Velasquillo, C, and Alcocer-Varela, J., Participation of the CD69 antigen in the T-cell activation process of patients with systemic lupus erythematosus.Scand. J. Immunol., 48, 196–200 (1998).
Dean, G. S., Tirrell-Price, J., Crawley, E., and Isenberg, D. A., Cytokines and systemic lupus erythematosus.Ann. Rheum. Dis., 59, 243–251 (2000).
Gerez, L., Shkolnik, T., Hirschmann, O., Lorber, M., Arad, G, and Kaempfer, R., Hyperinducible expression of the interferon-gamma (IFN-gamma) gene and its suppression in systemic lupus erythematosus (SLE).Clin. Exp. Immunol., 109, 296–303(1997).
Hirano, T., Interleukin 6 and its receptor: ten years later.Int. Rev. Immunol., 16, 249–84 (1998).
Hoffman, R. W., T cells in the pathogenesis of systemic lupus erythematosus.Clin. Immunol., 113, 4–13 (2004).
Huang, Y P., Perrin, L. H., Miescher, P. A., and Zubler, R. H., Correlation of T and B cell activitiesin vitro and serum IL-2 levels in systemic lupus erythematosus.J. Immunol., 141, 827–833(1988).
Ishihara, K. and Hirano, T., IL-6 in autoimmune disease and chronic inflammatory proliferative disease.Cytokine Growth Factor Rev., 13, 357–368 (2002).
Ishikawa, S., Akakura, S., Abe, M., Terashima, K., Chijiiwa, K., Nishimura, H., Hirose, S., and Shirai, T, A subset of CD4+ T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance.J. Immunol., 161,1267–1273 (1998).
Jacob, C. O. and McDevitt, H. O., Tumor necrosis factor alpha in murine autoimmune“lupus” nephritis.Nature (Lond), 331, 356–358(1988).
Kyttaris, V. C, Juang, Y T., and Tsokos, G. C, Immune cells and cytokines in systemic lupus erythematosus: an update.Curr. Opin. Rheumatol., 17, 518–22 (2005).
Lit, L. C, Wong, W. C. K., Tarn, L. S., Li, E. K. M., and Lam, C. W. K., Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus.Annals of the Rheumatic Diseases, 65, 209–215(2006).
Llorente, L, Zou, W., Levy, Y, Richaud-Patin, J., Wijdenes, J., Alcocer-Varela, J., Morel-Fourrier, B., Brouet, J. C, Alarcon-Segovia, D., Galanaud, P., and Emilie, D., Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.J. Exp. Med., 181, 839–844 (1995).
Llorente, L, Richaud-Patin, Y, Garcia-Padilla, C, Claret, E., Jakez-Ocampo, J., Cardiel, M. H., Alcocer-Varela, J., Grangeot-Keros, L, Alarcon-Segovia, D., Wijdenes, J., Galanaud, P., and Emilie, D., Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.Arthritis Rheum., 43,1790–1800 (2000).
Mok, C. C. and Lau, C. S., Pathogenesis of systemic lupus erythematosus.J. Clin. Pathol., 56,481–490 (2003).
Murphy, K. M., Ouyang, W., Farrar, J. D., Yang, J., Ranganath, S., Asnagli, H., Afkarian, M., and Murphy, T. L, Signaling and transcription in T helper development.Annu. Rev. Immunol., 18,451–94(2000).
Portales-Perez, D., Gonzalez-Amaro, R., Abud-Mendoza, C, and Sanchez-Armass, S., Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus.Lupus, 6, 48–56 (1997).
Reininger, L, Santiago, M. L, Takahashi, S., Fossati, L. and Izui, S., T helper cell subsets in the pathogenesis of systemic lupus erythematosus.Ann. Med. Interne. (Paris), 147, 467–471(1996).
Richards, H. B., Satoh, M., Shaw, M., Libert, C, Poli, V., and Reeves, W. H., Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.J. Exp. Med., 188, 985–90(1998).
Shacter, E., Arzadon, G. K., and Williams, J., Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin.Blood, 80, 194–202 (1992).
Stasiuk, L. M., Ghoraishian, M., Elson, C. J., and Thompson, S. J., Pristane-induced arthritis is CD4+ T-cell dependent.Immunology, 90, 81–86 (1997).
Takeno, M., Nagafuchi, H., Kaneko, S., Wakisaka, S., Oneda, K., Takeba, Y, Yamashita, N., Suzuki, N., Kaneoka, H., and Sakane, T., Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production.J. Immunol., 158, 3529–3538 (1997).
Takeuchi, T., Tsuzaka, K., Abe, T., Yoshimoto, K., Shiraishi, K., Kameda, H., and Amano, K., T cell abnormalities in systemic lupus erythematosus.Autoimmunity, 38, 339–346 (2005).
Theofilopoulos, A. N. and Lawson, B. R., Tumour necrosis factor and other cytokines in murine lupus.Ann. Rheum. Dis., 58(Suppl 1), 149–55 (1999).
Ucker, D. S., Ashwell, J. D., and Nickas, G., Activation-driven T cell death. I. Requirements for de novo transcription and translation and association with genome fragmentation.J. Immunol., 143, 3461–3469 (1989).
Uhm, W. S., Na, K., Song, G. W., Jung, S. S., Lee, T, Park, M. H., and Yoo, D. H., Cytokine balance in kidney tissue from lupus nephritis patients.Rheumatology (Oxford), 42, 935–938 (2003).
Xu, L, Zhang, L, Yi, Y, Kang, H. K., and Datta, S. K., Human lupus T cells resist inactivation and escape death by upregulating COX-2.Nat. Med., 10, 411–415 (2004).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Suk Chae, B., Shin, T.Y. Immunoregulatory abnormalities of T cells and hyperreactivity of B cells in theIn Vitro immune response in pristane-induced lupus mice. Arch Pharm Res 30, 191–198 (2007). https://doi.org/10.1007/BF02977694
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02977694